Valeritas Competitors, Revenue, Alternatives and Pricing

Claim your profile


Bridgewater, NJ USA
Total Funding:$333.9M
Industry:Medical Equip
Lead Investor(s):CRG L.P

Estimated Revenue & Financials

  • Valeritas's estimated annual revenue is currently $26.4M per year.(?)
  • Valeritas received $23.7M in venture funding in May 2016.
  • Valeritas's estimated revenue per employee is $425,774
  • Valeritas's total funding is $333.9M.

Employee Data

  • Valeritas has 62 Employees.(?)
  • Valeritas grew their employee count by -48% last year.
  • Valeritas currently has 4 job openings.

We are a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. We designed our first commercialized product, the V-Go Wearable Insulin Delivery Device, or V-Go, to help patients with Type 2 diabetes who require insulin to achieve and maintain their target blood glucose goals. V-Go is indicated for continuous subcutaneous infusion of insulin over 24 hours at preset rates and on-demand bolus dosing in two-unit increments in adult patients requiring insulin. V-Go is a small, discreet and easy-to-use disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery by using one type of insulin (fast-acting) at a continuous preset (background) basal rate over a 24-hour period and provides on-demand bolus dosing for meals and snacks. In numerous real-world analyses V-Go has consistently shown to lower A1C's with less insulin. The discreet and convenient basal-bolus insulin delivery method provided by V-Go empowers patients to simplify their insulin management thereby mitigating the need to plan their daily routine around multiple daily injections. V-Go is cleared for use in the United States and the E.U. is commercially available in the United States.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals